Nektar Therapeutics Stock News

Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.

Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.

The Global Targeted Therapeutics market size is growing at a CAGR of 6.7% over the forecast period of 2021-2026. Targeted therapy may be described as a treatment contemplated in the treatment of cancer. Targeted cancer therapy is also limited to molecularly

Royal Bank of Canada lifted its position in Nektar Therapeutics (NASDAQ:NKTR) by 155.7% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 14,087 shares of the biopharmaceutical companys stock after acquiring an additional 8,578 shares during the quarter. Royal Bank of Canadas holdings in Nektar Therapeutics were worth $242,000 as of its most recent SEC []

PALM BEACH, Fla. , Dec. 10, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer . Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Nektar Therapeutics (NASDAQ:NKTR) shares saw unusually-high trading volume on Thursday . Approximately 28,005 shares were traded during trading, a decline of 97% from the previous sessions volume of 1,105,866 shares.The stock last traded at $12.69 and had previously closed at $12.73. A number of equities research analysts recently commented on NKTR shares. BTIG Research lowered []

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Signature Bank, SolarEdge Technologies Inc. and FactSet Research Systems Inc. will be joining the S&P 500 index later this month, S&P Dow Jones Indices said late Friday. Out are Leggett & Platt Inc.

Morgan Stanley reduced its position in Nektar Therapeutics (NASDAQ:NKTR) by 8.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 477,014 shares of the biopharmaceutical companys stock after selling 42,117 shares during the quarter. Morgan Stanley owned 0.26% of Nektar Therapeutics []

Equities research analysts expect Nektar Therapeutics (NASDAQ:NKTR) to announce ($0.82) earnings per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Nektar Therapeutics earnings. The highest EPS estimate is ($0.74) and the lowest is ($0.89). Nektar Therapeutics posted earnings of ($0.65) per share during the same quarter last year, []

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

Nektar Therapeutics (NASDAQ:NKTR) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 1.84% to the previous days close as strong demand from buyers drove the stock to $11.62. Actively observing the price movement in the last trading, the stock closed the session at $11.41, falling within a range of $11.09 and Thinking About Buying Nektar Therapeutics Stock? Heres What You Need To Know. Read More »

Marshall Wace North America L.P. bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 33,724 shares of the biopharmaceutical companys stock, valued at approximately $579,000. A number of other large investors also recently modified their []

Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 3,000 shares of the companys stock in a transaction that occurred on Thursday, November 18th. The stock was sold at an average price of $12.69, for a total value of $38,070.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through []